MedTrace Logo

Presepsin Biomarker for Ventilator-associated Pneumonia Diagnosis in COVID-19 Patients

NCT04840940 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-04-19

No results posted yet for this study

Summary

This study is observational and double blind. It evaluates the validity of presepsin (a serum biomarker of bacterial infections) as early biomarker of Ventilator Associated Pneumonia. It will be measured at day 0 (ICU admission) and every 48 hours in every patient with Sars-Cov 2 interstitial pneumonia requiring invasive mechanical ventilation (see inclusion ad exclusion criteria) until Day 30, ICU discharge or ICU death. There will be no change in clinical practice and in pneumonia diagnosis. We will examine how the elevation of presepsin level could be an early marker of ventilator associated pneumonia or a marker of bacterial pneumonia at ICU admission, before the microbiological results or clinical diagnosis.

Conditions

  • Ventilator Associated Pneumonia
  • Covid19

Sponsors & Collaborators

  • San Luigi Gonzaga Hospital

    lead OTHER

Principal Investigators

  • Pietro Caironi · San Luigi Gonzaga Hospital

  • Guido Bussone · San Luigi Gonzaga Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2021-12-21
Completion
2021-12-21

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04840940 on ClinicalTrials.gov